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Abstract  
It is established that there is a relationship between inflammation and cancer development. The 
constant colonic inflammation typical of inflammatory bowel diseases is now considered a risk 
factor for colorectal cancer (CRC) development. The inflammatory network of signaling molecules 
is also required during the late phases of carcinogenesis, to enable cancer cells to survive and to 
metastasize. Oxidative reactions are an integral part of the inflammatory response, and are generally 
associated to CRC development. However, when the malignant phenotype is acquired, increased 
oxidative status induces antioxidant defenses in cancer cells, favoring their aggressiveness. This 
contradictory behavior of cancer cells towards redox status is of great significance for potential 
anticancer therapies. 
The paper summarizes the essential background information relating to the molecules involved in 
regulating oxidative stress and inflammation during carcinogenesis. Today’s understanding of their 
function in CRC stages might provide the foundations for future developments in CRC treatment. 
  
Introduction 
Colorectal carcinoma (CRC) is the third commonest cancer, with almost 1.4 million new 
cases and 0.7 million deaths worldwide in 2012; 500,000 new cases and 250,000 deaths have been 
reported in Europe. In Western countries, for incidence and mortality CRC is the second malignant 
neoplasm after breast cancer in women, and the third after lung and prostate cancers in men. Onset 
is rare before the age of 40; it is more frequent in older people, with a peak around the age of 80. 
The incidence of CRC is now increasing in the female population, because of lifestyle, which has 
become more uniform between the two sexes.
1
 
Inflammation has been considered to play a major role in the initiation, promotion and progression 
of CRC: the constant colonic inflammation typical of inflammatory bowel disease (IBD) may lead 
to Colitis-Associated Cancer (CAC), a subtype of CRC. More than 20% of patients with IBD 
develop CAC within 30 years of the disease onset, and more than 50% of them die as a result of 
malignant transformation.
2
 CAC usually affects younger persons, and is characterized by multiple 
lesions, located in more proximal segments of the colon mucosa compared to sporadic CRC. The 
duration of active IBD and the extent of inflamed colonic mucosa have been identified as two major 
risk factors for developing CRC. Further, the risk of developing cancer is much higher in IBD 
patients with primary sclerosing cholangitis, which is a predisposing factor for cancer of the biliary 
tract. The administration of non-steroidal anti-inflammatory drugs, especially 5-aminosalicylates, 
can reduce the development of dysplasia and colorectal carcinoma.
3
  
Infiltration and enhanced activation of inflammatory cells may initiate and further promote cancer 
development. These cells generate inflammatory cytokines, several of which play crucial roles in 
CRC carcinogenesis. Further, chronic inflammation in IBD exposes the intestinal mucosa to severe 
oxidative insult, which increases the risk of malignant transformation, promoting cell mutation and 
cancer proliferation. An inappropriate response of the mucosa-associated immune system to 
commensal and pathogenic microbiota, as occurs in IBD, may contribute to inducing excessive 
inflammatory and oxidative reactions by activated leukocytes, thus amplifying intestinal mucosa 
injury. Neutrophils and macrophages generate free radicals and other pro-oxidant molecules: the 
inflamed tissue of patients with active IBD shows an increased expression of reactive oxygen 
species (ROS). Oxidative stress and the associated mucosal damage play key roles in the 
pathogenesis of colitis, as well as in colorectal carcinogenesis.
4, 5
  
This review will focus on the roles of inflammation and oxidative stress in CRC initiation and 
progression.  Understanding how the molecules involved in these processes can function as sensors 
and modulators of cancer behavior may contribute to providing new therapeutic strategies against 
the development and progression of CRC. 
 
Inflammatory cells and CRC 
CRC may be taken as a model of the link between inflammation and cancer. Inflammation is driven 
by cytokines and chemokines, which may be produced by the tumor cells themselves or, more 
often, by cells recruited to the tumor microenvironment.  
Lymphocytic infiltration in CRC was thought to be associated with a better prognosis.
6 
The 
immunosurveillance system may recognize and eliminate the transformed malignant cells, or even 
small tumors in a quiescent state; this process may also lead to the deletion of single cells or small 
groups of metastatic cells. Conversely, lymphocytic infiltrate has been shown to promote 
carcinogenesis. It has been shown that adaptive immune response cells, recruited in CRC, can 
display either pro- or anti-tumoral activity. T lymphocytes may favor the development and 
progression of tumor-activating inflammation, whereas conversely they may act against the tumor, 
through immunosurveillance.
7
  
Similar activity has been observed in Tumor Associated Macrophages (TAM), whose polarization 
from the pro-inflammatory M1 to the pro-tumoral M2 phenotype has been confirmed to be a key 
event in the carcinogenesis of many malignant tumors, including CRC. The M2 phenotype produces 
several molecules that sustain malignant cell survival and proliferation, suppress the anti-tumoral 
adaptive immune response, modify extracellular matrix (ECM) proteins, and promote 
neoangiogenesis. Interestingly, the concomitant presence of both TAM phenotypes has been 
observed at the tumor front: the M1/ M2 macrophage ratio might be an important prognostic index 
for CRC patients.
8
 
There is some evidence that neutrophils may be associated with carcinogenesis, in the form of 
Tumor Associated Neutrophils (TAN), by acquiring the N2 pro-tumoral phenotype, similarly to 
macrophages. TAN tumor infiltration may be responsible for genetic instability, through the 
production of ROS, and may facilitate invasion, through the release of a large number of serine 
proteases and chemokines. 
9 
The important role played by TAN in tumor initiation and progression 
has been demonstrated in experimental models of colitis associated to carcinogenesis in mice 
10 
and 
in humans.
11
 
 
The key role of inflammatory molecules 
A large number of inflammatory molecules are involved during different steps of carcinogenesis; 
they act by influencing tumor cell growth, differentiation, and survival.  
The molecules most widely known to be involved in the inflammatory process are the ecosanoids 
(prostaglandins, prostacyclins, thromboxanes, and leukotrienes). In particular, increased activity of 
the inducible enzyme cyclooxygenase-2 (COX-2), which catalyzes prostaglandin (PG) synthesis, 
plays an important role in CRC carcinogenesis. Increased COX-2 expression has been detected in 
CAC animal models,
12
 as well as in the tissue of CRC patients, where it is associated to poor 
prognosis.
13
 The pro-neoplastic effect of COX-2 appears to be mediated by its major end product, 
PGE2, which can stimulate the tumor microenvironment to induce cancer stem cells.
14
 
Besides the classical inflammatory mediators just mentioned, cytokines and chemokines may act as 
tumor growth factors, and may, together with the serine proteinases, promote tumor invasion by 
inducing angiogenesis and suppressing the antitumor immune response. Specific pro-inflammatory 
cytokines, such as interleukins (ILs) IL-1, IL-6, IL-8 and Tumor Necrosis Factor-α (TNF-α), or the 
transcription factors required for the signals induced by these cytokines, including Nuclear Factor-
κB (NF-κB) and Signal Transducer and Activator of Transcription (STAT) 3, are thus now 
emerging as potential targets for anticancer therapy.
12
 
Although the first studies that found evidence for tumor promotion regulated by cytokines were on 
CAC, the same mechanisms may also apply to sporadic CRC: cytokines IL-1β, IL-6, and TNF-α 
have been shown to promote the development of both CAC and sporadic CRC.
15
 
TNF-α, which is produced during the early inflammatory response, increases vascular permeability, 
leading to recruitment of activated leukocytes at the tumor site.
12
 Notably, several different 
commensal and pathogenic bacterial strains have been found to activate TNF-α and IL-8 in IBD 
patients.
16
  
IL-8, with its receptor CXCR2, is the most strongly up-regulated cytokine in CRC. It enhances the 
proliferation and survival of cancer cells through autocrine activation, and promotes angiogenesis 
and neutrophil infiltration into the tumor. IL-8 is abundantly synthesized by N2 neutrophils,
9 
and its 
expression has been found to be elevated in patients with metastatic disease.
17
 It plays an important 
role in the process of tumor invasion, because of its direct involvement in up-regulating the 
expression of ECM serine proteinases, such as Matrix Metalloproteinases (MMPs). A positive 
correlation between IL-8 and MMP-9 has been reported in advanced stages of CRC.
18
 
IL-6 plays an important role in inflammation related to CRC pathogenesis: high levels of this 
cytokine have been detected in IBD, as well as in CRC patients. Most of the effects of IL-6 on 
cancer cells may be due to interleukin’s ability to activate the JAK/STAT signaling pathway.19 
Specific cytokines produced by tumor infiltrating T helper (Th) 17 CD4+ lymphocytes, such as IL-
17 and IL22, have been reported to be increased in experimental and human CRC; together with IL-
6 and TNF-α, these cytokines activate STAT3 and NF-B, and contribute to tumor promotion and 
progression. Inhibition of these transcription factors, in particular of STAT3, might down-regulate 
the production of cytokines by tumor infiltrating cells, consequently inhibiting CRC growth. 
20, 15
 
IL-23 is a cytokine that promotes Th17 cell development and survival and IL-17 related synthesis. 
Specific polymorphisms of the gene encoding for IL-23 receptor, as well as that for IL-17, have 
been associated with Crohn's disease (CD), ulcerative colitis UC), 
4 
and some clinical features of 
human CRC.
21
  
Transforming Growth Factor β (TGFβ) is a cytokine whose role in tumor development is 
paradoxical: it exhibits antitumor effects in the earliest phases of tumor growth, by inhibiting 
proliferation, promoting apoptosis, and suppressing the expression of tumor promoting pro-
inflammatory cytokines. It is widely accepted that mutations of the TGFβ pathway in epithelial cells 
predispose to, or facilitate, CRC development and growth.
22
 Conversely, during the later phases of 
tumor progression, the tumor cells require the TFGβ function in order to promote Epithelial-
Mesenchymal Transition and suppress the immune cells’ antitumor activity, thus facilitating 
metastasis.
23
 Notably, TANs acquire the N2 pro-tumoral phenotype in response to TGF.9 
MMPs, in particular the gelatinases MMP-9 and MMP-2, are serine proteinases whose main 
function is to degrade collagen IV, a major component of the basement membranes of epithelial 
tissues. MMP activity is essential in CRC development and invasiveness. During carcinogenesis, 
the main sources of production of MMPs are M2 macrophages and stromal cells,
8
 particularly in 
advanced stages of CRC. 
Our own experience with CRC patients has shown that MMP-9 levels are significantly higher in 
CRCs at stages III and IV (TNM classification), in both the peripheral blood and tumor tissue. A 
direct relation was also present among MMP-9, IL-8, and C reactive protein serum levels, all of 
which increased at more advanced tumor stages. Based on these findings, these molecules might be 
considered as reliable indexes of inflammation during CRC progression.
18
 Further, as-yet 
unpublished data confirm MMP-9 to be a reliable diagnostic factor for CRC, since preoperative 
MMP-9 serum levels effectively discriminated healthy subjects from cancer patients. However, 
MMP-9 alone showed a poor capacity to predict the onset of metastasis, independently of disease 
stage, at different times after surgical removal of the tumor mass.  
 
Inflammation-driven oxidative reactions in CRC  
Inflammation might be the link between oxidative stress and CRC, in which ROS are overproduced 
by activated leukocytes. ROS ant their oxidation products could thereby overwhelm the tissue’s 
antioxidant defenses, and contribute to the functional impairment that in all likelihood leads to 
dysplasia of the enteric mucosa. Inflammatory phagocytic cells, such as neutrophils and 
macrophages, present on their surface the enzyme responsible for the "respiratory burst", namely 
NADPH oxidase (NOX); this enzyme produces the ROS required for processing and killing 
bacteria. Upon contact with pathogens or specific cytokines, NOX converts oxygen to superoxide 
(O2 • ¯) which is then converted by antioxidant enzymes to H2O2 through superoxide dismutase 
(SOD), and to H2O and O2 through glutathione peroxidase (GPX) and catalase. Intestinal NOX1 
isoform, as well as NOX complex members NOX Organizer 1 (NOXO1) and NOX Activator 1 
(NOXA1), are reported to be significantly overexpressed in CRC tissue compared to adjacent 
normal colon mucosa.
24
  
The phagocytic isoform, NOX2, is potently activated by TNFα, and NoxO1 gene transactivation 
induced by this cytokine is reported in human colon epithelial cells, suggesting that this oxidase 
may be a potential target in colon inflammation.
25
 
Reactive nitrogen species (RNS) that are produced by phagocytes during inflammation, i.e. nitric 
oxide (NO), through inducible nitric oxide synthase (iNOS) and peroxynitrite (OONO
·
), have also 
been implicated in cancer development. The oxidation of various cellular macromolecules and the 
modulation of gene expression, both brought about by these reactive species, are thought to be one 
of the main mechanisms of cancer initiation.
5
  
The induction of DNA mutations by ROS attack is considered to be principally involved in the early 
events of colon carcinogenesis linked to inflammatory processes. Reaction of the hydroxyl radical 
at the C-8 position of deoxyguanosine induces formation of 8-hydroxy-2′-deoxyguanosine (8-
OHdG), which might play a role in mutagenic events and genetic instability in the early phases of 
cancer initiation and promotion. Levels of this marker of oxidative DNA damage have been found 
to be twice normal in experimental colitis induced in rats treated with dextran sodium sulfate (DSS). 
Concomitant administration of the COX-2 inhibitor nimesulide clearly demonstrated a net decrease 
in 8-OHdG production in colonocytes.
26
 Increased levels of 8-OHdG have been found in the plasma 
of patients suffering from UC or CD.
27
 NO-dependent oxidative DNA lesions producing G:C to 
T:A base transversions have been associated to TP53 mutations in inflamed colon portion of UC 
patients.
28
 
Mitochondria are the main sites for ROS generation together with NADPH oxidase.  Mitochondrial 
DNA (mtDNA) is thus particularly exposed to ROS damage, being localized close to the 
intracellular mitochondria electron transport chain. Increased mutations of mtDNA, and the high 8-
OHdG tissue concentrations found in mucosal specimens from patients with UC, have been related 
to the high incidence of CRC in these subjects.
29
  
Protein oxidation leads to the alteration of both structural and functional proteins, which are 
involved in the maintenance of cell integrity. Special attention should be paid to the oxidative 
modification of enzymes that may be inhibited in specific activities, including inactivation of the 
DNA mismatch repair system, thus damaging the protein complex responsible for DNA repair.
5
  
Polyunsaturated fatty acids (PUFAs) are highly susceptible to free radical attack on double bonds, 
whose breaking and rearrangement leads to the generation of more stable aldehyde end-products, 
able to react with cellular structures. In particular, the aldehydes produced during the oxidative 
breakdown of PUFA have been considered as final mediators of the toxic effects elicited by lipid 
peroxidation in cells and tissues. Arachidonic acid is the ω6-PUFA most closely involved in both 
inflammation (being the substrate for the enzymatic production of prostaglandins through COXs 
activity) and lipid peroxidation: its breakdown generates the end-product 4-hydroxy-2,3-nonenal 
(HNE), which has been shown to react more strongly than do other aldehydes with biomolecules 
containing amino and thiol groups, thus modifying the proteins involved in cell signaling pathways 
that induce the antioxidant response. Rapid conjugation of HNE with glutathione (GSH) markedly 
depletes this antioxidant in different cell types. Further, HNE reacts with all four DNA bases, in 
particular making more efficient adducts with deoxyguanosine.
30
  
 Oxidative-stress-activated signaling pathways and antioxidant response in CRC 
Although oxidative reactions are often associated to the early phase of cancer, mainly in that they 
induce DNA damage, they may also be involved in the antioxidant response activation that can 
facilitate tumor progression and invasiveness, rather than having antitumor effects. Redox sensitive 
signaling pathways that are activated during inflammation in CRC are the principal actors of this 
phenomenon. 
Besides its involvement in generating ROS during cancer initiation, NOX also plays an essential 
role in epithelial tumor cell proliferation and invasion. NOX1 is expressed in the human colon, 
depending on the degree of cell differentiation, its expression being up-regulated in adenomas and 
well-differentiated carcinomas.
31
 Conversely, ROS production by NOX1 can trigger the 
“angiogenic switch”, by inducing angiogenic factors such as vascular endothelial growth factor and 
MMP-9, which promote epithelial tumor cell vascularization and proliferation.
32
 
A large proportion of CRCs show constitutive activation of transcription factors, such as the redox-
sensitive transcription factor NF-κB, and the signal transduction molecules that are essential 
constituents of multiple inflammatory pathways. The aberrant activation of NF-κB is reported in 
over 50% of CRCs.
33
  
Activation of NF-κB via ROS generation during inflammation may support carcinogenesis. There is 
some evidence that antiapoptotic members of the B-cell leukemia/lymphoma 2 (Bcl2) family, which 
have an antioxidant function and are deregulated in cancer, are highly regulated NF-κB target 
genes.
34
 Tumor cells with activated NF-κB acquire resistance to chemotherapics: inactivation of 
NF-κB greatly increases their sensitivity to these agents.35 The NF-κB signaling pathway may be 
persistently activated in inflammatory cells and enterocytes, by Toll-like receptors (TLRs) and Nod-
like receptors (NLRs), which are up-regulated in IBD.
4
 Activation of NF-κB in myeloid cells 
(especially macrophages and dendritic cells of the intestinal lamina propria) determines the 
production of cytokines that act as growth factors for already altered enterocytes.
33
 
In some cases, prolonged constitutive activity of NF-κB in the cancer cell nucleus is determined by 
the activity of STAT3, which has been found to be persistently activated in CRC. STAT3 belongs 
to a family of transcription factors that are involved in mediating cell growth and differentiation 
during immune and inflammatory processes. Certain STATs are specifically activated by Janus 
kinases (JAKs), a group of tyrosin kinase receptors whose ligands are cytokines. Genetic variations 
in JAK/STAT signaling pathway appear to influence CRC carcinogenesis.
36
 Interestingly, crosstalk 
between STAT3 and the mammalian target of rapamycin complex 1 (mTORC1), which controls 
anabolic cell growth and proliferation, can promote CRC in colitic mice.
37
 
A study on Bacteroides enterotoxigenic fragilis, a commensal bacterium found in 20-35% of adults, 
found that this microbe promoted CRC formation in APC knockout mice by activating the Th17-
STAT3 dependent pathway mechanism; the use of anti-IL-17 antibodies, alone or combined with 
anti-IL-23 antibodies, significantly inhibited colon tumor formation.
38
  
Very recent studies indicate that expression of redox-sensitive Nuclear Factor-Erythroid 2-Related 
Factor 2 (NRF2) is deregulated in various human cancers, including CRC, suggesting its possible 
involvement in carcinogenesis and therapy resistance. In normal cells, NRF2 plays a central role in 
cellular defense against oxidative stress. Upon its activation, NRF2 is set free from its own negative 
regulator, Kelch-like ECH-associated protein 1 (KEAP1), whereupon it translocates to the nucleus 
and binds to response elements on DNA, known as antioxidant response elements (AREs) or 
electrophile response elements (EpREs). It is able to do so by regulating the expression of genes 
encoding for redox balancing proteins, including heme oxygenase (HO)-1, SOD, enzymes 
necessary for GSH synthesis and recovery (glutamate–cysteine ligase catalytic/modulatory subunits 
GCLC/ GCLM, GSH-S-reductase), and thioredoxin (TXN) production (TXN-reductase-1, 
peroxiredoxin-1/4). NRF2 also regulates many other genes, particularly those involved in cell 
differentiation and proliferation.
39
  
NRF2 is now considered to play a dual role in tumorigenesis: numerous reports indicate that 
activation of NRF2 can suppress carcinogenesis in many malignant tumors, especially at the earliest 
stages.
39
 Nevertheless, sustained activation of NRF2 occur in malignant tumors. In some cancers, 
mutations in Nrf2 or Keap1 that enhance NRF2 activity have been associated with resistance to 
standard chemotherapy and poor survival.
40
 NRF2 may also promote cancer cell proliferation and 
tumorigenesis, by maintaining the redox balance and generating antioxidants in cancer cells. Recent 
studies have revealed that glutathione is critical for cell proliferation; therefore, enhancement of 
GSH synthesis is another important effect of NRF2 in accelerating cancer cell proliferation.
41
 
Notably, NRF2 may participate in protection against inflammation by inhibiting NF-κB.42 
Conversely, it is also conceivable that NF-κB may activate NRF2 as a result of oxidative stress 
during inflammation. This latter effect has recently been observed in acute myeloid leukemia cells, 
in which NRF2 expression was reduced by NF-κB inhibitors.43 
Among different NRF2 target proteins, HO-1 may have oncogenic potential in cancer cell 
proliferation, invasion, and resistance to anticancer treatment. HO-1 is a microsomal antioxidant 
enzyme, which is activated by a wide range of stimuli, including ROS, to catabolize free heme, thus 
preventing free-radical production through the Fenton reaction, resulting in decreased oxidative 
stress, attenuated inflammatory response, and inhibited apoptosis.
39
 HO-1 has been found to be up-
regulated in CRC compared to surrounding normal tissue; its overexpression in cancer cells 
provides cellular resistance against ROS-mediated anticancer therapies.
44
 Moreover, HO-1 
accelerates tumor vascularization and increases cancer cells’ metastatic potential because of its pro-
angiogenic properties.
45
 Although HO-1 up-regulation has been found to exert pro-tumoral action, 
some studies report that CRC patients with high expression of this enzyme displayed longer overall 
survival times. HO-1 was found to decrease the migration and survival of cancer cells.
46
 Finally, its 
expression was reported to be associated with a lower rate of lymphatic invasion, and a tendency 
towards fewer lymph-node metastases; it was also found to be weaker at advanced stages of CRC, 
suggesting HO-1 may be a marker of genetic stability.
47
 Notably, the severity of DNA damage was 
found decreased at advanced stages of CRC, suggesting that oxidative reactions play different roles 
during different phases of carcinogenesis.
48
 
Thus, the combination of enhanced NRF2 activity with HO-1 induction and antioxidant increase 
appears to be protective in normal cells, and beneficial during the premalignant phases of 
carcinogenesis. However, it is undesirable at later stages of CRC, when it increases both cell 
survival and the progression to fully malignant cancer cells, which finally become resistant to 
therapy. 
 
Conclusions and future directions 
The substantial number of studies confirming the close relationship between chronic inflammation 
and oxidative stress in CRC carcinogenesis has encouraged many researchers to investigate the 
different pathways that may be involved in these processes, whose mutual cross-talk opens a new 
window for understanding these complicated phases of cancer development and progression. For 
many years, ROS have been thought to be important molecules, favoring early phases of CRC, 
while antioxidants have long been considered to be possible anticancer tools. However, numerous 
studies now show that an increased antioxidant status in cancer cells may activate survival and 
proliferation signaling pathways, making the cells resistant to the toxic effects of 
chemo/radiotherapy. This phenomenon is closely related to the activation of important molecules 
that modulate the cellular antioxidant response (Fig.1). Based on this observation, specific 
molecules involved in oxidative damage and inflammatory processes, which might enable the 
different phases of CRC to be characterized, still require investigation. Thus research targeting 
these molecules, and further investigating the antioxidant capacity of cancer cells, could be a 
promising approach for future therapeutic attempts in CRC treatment. 
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Figure Legend 
Figure 1. Inflammation and oxidative reactions are implicated in different phases of colorectal 
carcinogenesis.  
Pre-existing inflammation can result in mutations and epigenetic changes that favor tumor 
initiation. Reactive Oxygen/Nitrogen species (ROS/RNS), pro-inflammatory cytokines, growth 
factors and prostaglandins produced by activated inflammatory/immune cells, induce mutations and 
genomic alterations resulting in the appearance of premalignant cells (see “damaged enterocyte”) 
that proliferate and survive in response to these stimuli. In such microenvironment, during early 
stages of malignant transformation, inflammatory infiltrate is typically consisted of cells that 
express pro-inflammatory phenotype, such as Tumor Associated Macrophages (TAM) 1, Tumor 
Associated Neutrophils (TAN) 1 and T helper (Th) 17 lymphocytes. These cells are responsible for 
transcription factors Nuclear Factor-κB (NF-κB) and Signal Transducer and Activator of 
Transcription (STAT) 3 activation, and also for NADPH oxidase (NOX) up-regulation, which 
represent the major key events implicated in the pathogenesis of inflammation-associated tumor 
development.  Furthermore, activation of Toll-like receptors (TLRs) and Nod-like receptors (NLRs) 
by intestinal microbiota may contribute to inflammation through NF-κB and STAT3 activation. 
NOX and mitochondria are chief molecules responsible for ROS generation and related oxidation 
products able to induce structural and functional damage of important molecules involved in cell 
growth and proliferation. 
Normally, oxidative insult in enterocytes is counteracted by cellular antioxidant defenses, mainly 
through the up-regulation the redox sensitive Nuclear Factor-Erythroid 2-Related Factor 2 (NRF2), 
which induces antioxidant molecules, such as glutathione (GSH), heme oxygenase (HO)-1, 
superoxide dismutase (SOD) and thioredoxin (TXN). 
Conversely, when cells acquire malignant phenotype (see “tumor cell”), the increased antioxidant 
response and the elevated production of antioxidants enables them to progress and facilitate 
invasion.  Notably, at these cancer stages inflammatory infiltrate is replaced by cells with pro-
tumoral activity, i.e. TAM 2, TAN 2 and Th1, which mainly synthesized different growth factors 
and proteinases sustaining tumor survival and invasiveness. 
 
 
 
